On Friday, Shares of Microsoft Corporation (NASDAQ:MSFT), lost -1.24% to $46.86.
On Monday, Microsoft Corporation, declared that Windows 10 will be accessible July 29 in 190 countries. Windows 10 will assist people be more productive and have more fun, with a personal and natural experience that works across all their devices. Familiar, yet better than ever, Windows 10 will deliver ongoing feature innovations and security updates. Windows 10 will be accessible as a free upgrade to people using Windows 7 and Windows 8.1, enabling hundreds of millions of people around the world to upgrade to Windows 10 for free.
“Windows 10 is a new generation of Windows designed to empower you to do great things,” said Terry Myerson , executive vice president, Microsoft. “Windows 10 starts to deliver on our vision of more personal computing, defined by trust in how we protect and respect your personal information, mobility of the experience across your devices, and natural interactions with your Windows devices, counting speech, touch, ink and holograms.”
Microsoft Corporation develops, licenses, markets, and supports software, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system.
Shares of Amarin Corporation plc (NASDAQ:AMRN), declined -0.43% to $2.31, during its last trading session.
The Nasdaq Biotechnology Index is up significantly over the last 5 years with a good majority of positive momentum kicking in during the last 18 months. Since levels hovering around 830 this time in 2010, you can quickly start to see the massive growth that this market has seen especially since the NBI hit over 3,900 this year. The sharpest enhance on the index hasn’t been until recently from 2014- present and with the amount of IPO’s and mergers & acquisitions buzz, biotech stocks have captured the interests of many. Oncothyreon, Inc. (ONTY), Amarin Corp. Plc (AMRN), and Accurexa Inc. (ACXA) have begun to become more familiar with recently’s biotech investors.
Oncothyreon, Inc. declared this week that Robert Kirkman, M.D., President and Chief Executive Officer, is planned to present at the Jefferies 2015 Healthcare Conference in June. Share price of Oncothyreon has raised by as much as 158% since the first of May. The Company has two drug candidates in development, ONT-10, a therapeutic vaccine targeting MUC1, a glycoprotein amplified in most solid epithelial tumor cancers and common non-solid tumors, and ONT-380, an orally active, reversible and small molecule selective inhibitor of human epidermal growth factor receptor 2 (HER2). HER2 is also amplified in many types of cancers, counting breast, ovarian and stomach.
Amarin Corp. Plc also declared this week that Amarin’s President and Chief Executive Officer, John F. Thero, is planned to present a general company update at the Jefferies 2015 Global Healthcare Conference. Though some are speculating on short interest in Amarin, price movement has suggested the opposite to that over the last 3 days. Since opening the week at $1.90, shares of AMRN have jumped by as much as 47% following Thursday highs of $2.80. Amarin focuses more on cardiovascular health. Presently the company’s first product Vascepa(R) (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product comprises Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
At the end of Friday’s trade, Shares of E. I. du Pont de Nemours and Company (NYSE:DD), lost -0.60% to $71.01.
E. I. du Pont de Nemours and Company issued the following statement in response to the U.S. Environmental Protection Agency’s (EPA) projected rulemaking as they work toward setting blending targets under the Renewable Fuels Standard (RFS) for 2014, 2015 and 2016 later this year:
DuPont is disappointed with the EPA’s projected rule on the 2014, 2015 and 2016 Renewable Volume Obligations under the RFS. Our primary concern continues to be that the EPA is proposing a flawed methodology to fundamentally change how the annual volumes for renewable fuel are calculated causing reductions in annual biofuel volumes. Instead of setting biofuels volumes, as required by statute and based on the industry’s ability to supply fuel, EPA has injected infrastructure considerations into the calculation. This approach undermines fundamental principles of the RFS which have been the foundation for the economic, energy security and environmental successes of the renewable fuel sector in the United States. The RFS has made homegrown renewable fuel 10 percent of our nation’s gasoline supply, lowered greenhouse gas emissions by 21 million metric tons, added $500 billion in value to America’s farmlands, lowered gas prices and created a real choice at the pump.
The uncertainty over the RFS has already reduced the investment momentum in the advanced and cellulosic sectors in the United States; this will only continue if EPA does not change course in the final RVOs for 2014, 2015 and 2016. The renewable fuels industry is global in nature with substantial, long-term business potential. DuPont will continue to vigorously pursue every opportunity to enable the growth of the renewable fuel and renewable materials sectors here and around the world. We remain committed to this industry and to bringing world-class technology and sustainable best practices to market to spur the growth of renewable industries worldwide.
E. I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides. Its Electronics & Communications segment provides various materials and systems, counting photopolymers and electronic materials for photovoltaic products, consumer electronics, displays, and advanced printing.
Finally, Discovery Communications, Inc. (NASDAQ:DISCA), ended its last trade with 2.69% surge, and closed at $33.94.
Belk, Discovery Education and the International Society for Technology in Education (ISTE) declared the winners of the third annual Belk Service Learning Challenge. Designed to support educators, and based on research that students who take part in service learning initiatives demonstrate improved problem-solving skills and raised interest in academics, the challenge encouraged middle school students to assist improve their communities through undertaking a service-learning project of their choice.
The Belk Service Learning Challenge invited students to work in teams of up to four classmates with the support and guidance of a teacher/mentor to identify an issue in their local community and design an action plan to implement a solution. The three grand prize winning teams will each receive $2,000 per student team member and a $2,000 teacher award. The grand prize winners comprise:
Team: “Prosthetic Kids” from District 5 of Lexington & Richland Counties’ CrossRoads Middle School
Location: Columbia, SC
Project Description: Students used 3D printers to create prosthetic hands for children in need, and hosted a school-wide Hand-A-Thon event to assemble more than 20 additional prosthetic hands.
Discovery Communications, Inc. operates as a media company. The company operates through U.S. Networks; International Networks; and Education and Other segments. It owns and operates television networks under the brands, such as Discovery, TLC, Animal Planet, Investigation Discovery, Science, Velocity, Discovery Family, American Heroes, Destination America, Discovery Life, Oprah Winfrey network, Eurosport, DMAX, and Discovery Kids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
